Sinovac Biotech (SVA) Earning Somewhat Positive Media Coverage, Analysis Shows
Press coverage about Sinovac Biotech (NASDAQ:SVA) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sinovac Biotech earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 48.2045132011591 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties (finance.yahoo.com)
- What Does Sinovac Biotech Ltd’s (NASDAQ:SVA) Ownership Structure Look Like? (finance.yahoo.com)
- Sinovac Newly-Elected Board of Directors’ Response to the Announ – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- Sinovac Newly-Elected Board of Directors’ Response to the Announcement of the Purported Re-Election of All Directors at the February 6, 2018 Annual General Meeting (finance.yahoo.com)
- Baxalta (BXLT) vs. Sinovac Biotech (SVA) Financial Comparison (americanbankingnews.com)
Separately, BidaskClub downgraded Sinovac Biotech from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 7th.
COPYRIGHT VIOLATION NOTICE: “Sinovac Biotech (SVA) Earning Somewhat Positive Media Coverage, Analysis Shows” was first posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.mareainformativa.com/2018/03/16/sinovac-biotech-sva-receives-daily-news-sentiment-rating-of-0-10-updated-updated-updated.html.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.